Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tamoxifen. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 known ✓ | P03372 | 8/20 | 0.95 |
| ▸ | ESR2 | Q92731 | 6/20 | 0.95 |
| ▸ | MAPT | P10636 | 3/20 | 0.95 |
| ▸ | MEN1 | O00255 | 3/20 | 0.95 |
| ▸ | TP53 | P04637 | 3/20 | 0.95 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.95 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.95 |
| ▸ | ESRRG | P62508 | 3/20 | 0.95 |
| ▸ | PGR | P06401 | 2/20 | 0.95 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.95 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.95 |
| ▸ | HTR6 | P50406 | 2/20 | 0.95 |
| ▸ | NPC1 | O15118 | 1/20 | 0.95 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.95 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.95 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.95 |
| ▸ | EGFR | P00533 | 1/20 | 0.95 |
| ▸ | GBA1 | P04062 | 1/20 | 0.95 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.95 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.95 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tamoxifen SCHEMBL60433 | 1.00 | ESR1 (0.95) | ESR1ESR2MAPTMEN1TP53 | |
| Tamoxifen SCHEMBL119181 | 0.97 | ESR1 (1.00) | ESR1ESR2MAPTMEN1TP53 | |
| Tamoxifen SCHEMBL4084 | 0.97 | ESR1 (1.00) | ESR1ESR2MAPTMEN1TP53 | |
| Tamoxifen SCHEMBL17262082 | 0.97 | ESR1 (1.00) | ESR1ESR2MAPTMEN1TP53 | |
| Tamoxifen SCHEMBL1056785 | 0.97 | ESR1 (1.00) | ESR1ESR2MAPTMEN1TP53 | |
| Tamoxifen SCHEMBL4085 | 0.97 | ESR1 (1.00) | ESR1ESR2MAPTMEN1TP53 | |
| Tamoxifen SCHEMBL17262111 | 0.97 | ESR1 (1.00) | ESR1ESR2MAPTMEN1TP53 | |
| SCHEMBL29659348 | 0.97 | ESR1 (1.00) | ESR1ESR2MAPTMEN1TP53 | |
| Tamoxifen SCHEMBL6266439 | 0.96 | ESR1 (0.92) | ESR1ESR2MAPTMEN1TP53 | |
| Tamoxifen SCHEMBL5789295 | 0.96 | ESR1 (0.97) | ESR1ESR2MAPTMEN1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 7396 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260116861-A1 | ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS | THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) | 2026-04-30 | — | — | US | claimed |
| US-12522572-B2 | Isoxazole hydroxamic acids as histone deacetylase 6 inhibitors | THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) | 2026-01-13 | — | — | US | claimed |
| US-20240343697-A1 | ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS | THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) | 2024-10-17 | — | — | US | claimed |
| US-11345956-B2 | Methods and compositions related to prostate cancer therapeutics | THE JOHNS HOPKINS UNIVERSITY (US) | 2022-05-31 | — | — | US | claimed |
| US-11207289-B2 | Use of benzofuran lignans to induce IL-25 expression and suppress mammary tumor metastasis | ACADEMIA SINICA (TW) | 2021-12-28 | — | — | US | claimed |
| US-10953073-B2 | XTEN conjugate compositions and methods of making same | AMUNIX PHARMACEUTICALS, INC. (US) | 2021-03-23 | — | — | US | claimed |
| US-20210060040-A1 | CANNABINOID RECEPTOR MODULATORS | ARENA PHARMACEUTICALS, INC. | 2021-03-04 | — | — | US | claimed |
| EP-3191114-B1 | OCCIDIOFUNGIN FORMULATIONS AND USES THEREOF | UNIV MISSISSIPPI STATE (US) | 2021-03-03 | — | — | EP | claimed |
| US-20200289454-A1 | USE OF BENZOFURAN LIGNANS TO INDUCE IL-25 EXPRESSION AND SUPPRESS MAMMARY TUMOR METASTASIS | Yang, Ning-Sun (TW) | 2020-09-17 | — | — | US | claimed |
| US-20200270362-A1 | MSLN TARGETING TRISPECIFIC PROTEINS AND METHODS OF USE | HARPOON THERAPEUTICS, INC. | 2020-08-27 | — | — | US | claimed |
| WO-2008039254-A2 | RNA NANOPARTICLES AND NANOTUBES | GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2008-04-03 | — | — | WO | claimed |
| EP-1017366-A4 | SOLID COPRECIPITATES FOR ENHANCED BIOAVAILABILITY OF LIPOPHILIC SUBSTANCES | PHARMOS CORP (US) | 2006-03-22 | — | — | EP | claimed |
| US-20040092583-A1 | Treatment for inhibiting neoplastic lesions | SHANAHAN-PRENDERGAST ELIZABETH (IE) | 2004-05-13 | — | — | US | claimed |
| EP-1351678-A2 | TREATMENT FOR INHIBITING NEOPLASTIC LESIONS USING INCENSOLE AND/OR FURANOGERMACRENS | Shanahan-Prendergast, Elizabeth (IE) | 2003-10-15 | — | — | EP | claimed |
| WO-2002053138-A2 | TREATMENT FOR INHIBITING NEOPLASTIC LESIONS USING INCENSOLE AND/OR FURANOGERMACRENS | SHANAHAN-PRENDERGAST ELISABETH (IE) | 2002-07-11 | — | — | WO | claimed |
| US-6387955-B1 | THERAPY FOR ANGIOGENESIS | PHARMOS CORPORATION (IL) | 2002-05-14 | — | — | US | claimed |
| EP-1017366-A1 | SOLID COPRECIPITATES FOR ENHANCED BIOAVAILABILITY OF LIPOPHILIC SUBSTANCES | PHARMOS CORPORATION (US) | 2000-07-12 | — | — | EP | claimed |
| US-6083990-A | Enhanced anti-angiogenic activity of permanently charged derivatives of steroid hormones | PHARMOS CORPORATION (US) | 2000-07-04 | — | — | US | claimed |
| US-5891469-A | IMPROVED ORAL DELIVERY AND ENHANCED BIOAVAILABILITY OF LIPOPHILIC SUBSTANCES USING COMPOSITIONS CONTAINING TOCOPHEROL POLYETHYLENE GLYCOL SUCCINATE | PHARMOS CORPORATION (US) | 1999-04-06 | — | — | US | claimed |
| WO-1998008490-A1 | SOLID COPRECIPITATES FOR ENHANCED BIOAVAILABILITY OF LIPOPHILIC SUBSTANCES | PHARMOS CORPORATION (US) | 1998-03-05 | — | — | WO | claimed |